Jerry Call

About Jerry Call

This author has not yet filled in any details.
So far Jerry Call has created 54 blog entries.

Clinical Registry Study Planned by ASCO

American Society of Clinical Oncology (ASCO) is planning its first-ever clinical registry study, the Targeted Agent and Profiling Utilization Registry (TAPUR).  ASCO plans should increase patient access to off-label drugs and match patients with [...]

By |2018-07-06T13:59:34-04:00January 6th, 2015|Gleevec, News, Patient Support, Side Effects, Stivarga, Sutent|

Join Our Tissue Bank – Help the LRG Find A Cure

Join our Tissue Bank - Help the LRG in the search for a cure. Wildtype GIST tissue is needed for a current LRG Research Team project. If you or a loved one are a wildtype GIST patient, please help the LRG Research Team in its search for the cure by donating your tissue.

By |2019-09-20T12:53:09-04:00April 1st, 2013|Advocacy, News, Patient Registry, Tissue Bank|

First report of a GIST patient responding to a BRAF inhibitor

First report of a GIST patient responding to a BRAF inhibitor. Dr. Gerald Falchook and colleagues at MD Anderson Cancer Center provided the first report of a GIST patient responding to a BRAF inhibitor. The BRAF gene is frequently mutated in melanoma and BRAF inhibitors provide one of the most important therapies available for melanoma patients

By |2019-09-20T12:57:43-04:00March 14th, 2013|News, Research|

Imatinib Plasma Levels Revisited – An editorial post by Jerry Call

Since we have gotten a number of questions about Gleevec (imatinib) plasma levels and testing, I think it’s time to revisit the subject, especially for newer members. Since this is a very complex subject, this may take a few emails and a few days.

By |2019-04-08T09:01:29-04:00January 21st, 2013|Gleevec, News|

Sutent Treatment Use Trial Results

Patients with GIST who received sunitinib using a flexible dose approach to manage adverse events remained on treatment longer than those who received the strict dose/schedule and exhibited better clinical outcomes (longer time to tumor progression and longer overall survival).

By |2019-09-20T13:24:08-04:00January 9th, 2013|Coping with GIST, News, Side Effects, Sutent|
Go to Top